摘要
目的研究奥拉西坦联合瑞舒伐他汀对高血压脑梗死患者的C反应蛋白(CRP)、血小板聚集率(PAG)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)及核转录因子(NF-κB)水平的影响。方法研究对象选取该院2017年2月‐2018年1月收治的高血压脑梗死患者98例,采用随机数字法,以每组49例为准,将其分为对照组和观察组。对照组患者接受神经内科常规治疗,观察组患者在此基础上采取奥拉西坦、瑞舒伐他汀联合治疗。比较两组患者的治疗疗效以及治疗前后的CRP、PAG、IL-1β、IL-6及NF-κB水平指标。结果观察组的治疗总有效率(91.84%)明显高于对照组(63.27%)(χ~2=11.49,P=0.000);治疗后,观察组患者的CRP、PAG、IL-1β、IL-6及NF-κB水平均明显低于对照组(P <0.05)。结论奥拉西坦联合瑞舒伐他汀对高血压脑梗死患者的临床疗效显著,可明显改善血凝情况和神经系统损伤情况,提高机体调节能力,值得临床推广。
【Objective】To investigate the effect of oxiracetam combined with rosuvastatin on C-reactive protein(CRP), platelet aggregation(PAG), interleukin-1β(IL-1β) and interleukin-6(IL-6) and nuclear transcription factor(NF-κB) levels in patients with hypertensive cerebral infarction.【Methods】Ninety-eight cases of hypertensive cerebral infarction patients admitted in our hospital between February 2017 and January 2018 were selected. Using random number method, patients were divided into control group and observation group with 49 cases in each group. The patients in the control group received routine treatment in cerebral medicine. The patients in the observation group were treated with oxiracetam and rosuvastatin on this basis. The therapeutic efficacy between the two groups was compared, as well as the levels of CRP, PAG, IL-1β, IL-6, and NF-κB before and after treatment. 【Results】The total effective rate of treatment in the observation group(91.84%) was significantly higher than that in the control group(63.27%)(χ^2=11.49, P =0.000);after treatment, CRP, PAG, IL-1β, IL-6, and NF-κB levels of patients in the observation group were significantly lower than those in the control group(P <0.05).【Conclusion】Oxiracetam combined with rosuvastatin has a significant clinical effect on patients with hypertensive cerebral infarction. It can significantly improve the condition of hemagglutination and damage to the nervous system and improve the body’s regulation ability. It is worthy of promotion in the clinic.
作者
刘睿
LIU Rui(Department of Neurology,Hengyang First People's Hospital,Hengyang,Hunan 421002,China)
出处
《中国医学工程》
2018年第12期21-24,共4页
China Medical Engineering